Nothing that landed this week stood on its own. A valve that grows with a child, a liquid embolic heading into its pivotal, a personalized spine implant — each one needed something outside the device to cooperate: a payment code switching on, a factory staying dry, an IPO window that would open. Two of those didn't. The most consequential thing FDA did all week was pick a vibrating crib mattress.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🫀 FDA approves the first heart valve built to grow with the patient
Edwards Lifesciences’ Autus Size-Adjustable Valve won premarket approval for children with congenital pulmonary valve disease. It implants at roughly 13mm and expands by catheter to about 22mm, and it is the first FDA-approved valve using polymeric leaflets rather than animal tissue. Sixty-two patients across 12 US sites, three frame fractures, no deaths or strokes. The win isn’t the valve, it’s the reoperations it removes from a child’s life — and from the lifetime cost case.
FDA
2. 🧠 Terumo buys into the subdural hematoma race before the pivotal reads
Terumo Neuro agreed to buy Arsenal Medical and NeoCast, an investigational solvent-free liquid embolic for middle meningeal artery embolization in chronic subdural hematoma. Terms weren’t disclosed. First-in-human data showed 96% of patients clearing at least half their hematoma volume and 75% resolving completely; FDA granted an IDE for the RADIANT pivotal trial against Medtronic’s Onyx, and patients are already enrolling. Buying the asset before the pivotal reads is what it costs not to be third into MMA embolization.
Terumo Neuro
3. 🏭 A July flood takes $22M off Integra’s year
Flash flooding in July at Integra LifeSciences’ East Side Cincinnati plant damaged equipment and inventory at the site making Mayfield cranial stabilization and Budde halo retractors. Integra now sees roughly $7 million off Q3 and another $15–20 million across 2026, with full recovery pushed to Q2 2027. Guidance fell to $1.634–1.654 billion and the stock dropped about 16%. Single-site concentration is a risk nobody prices until the creek comes up.
MassDevice
📋 You probably already know which part of your commercial case is weakest.
Most teams do. What’s harder is knowing what it’ll cost you at your next milestone, and what to do about it first. The free Commercial Readiness Check from RŌG Health takes two minutes and scores your case across five dimensions — buyer, evidence, economics, adoption, and capability — then tells you where you’re exposed and what to settle before you go.
Sponsored by RŌG Health
4. 🏠 FDA picks its first five for the home-readmissions challenge
CDRH named the first five participants in READI-Home: BD’s capillary self-collection kit, Epitel’s wearable EEG, Current Health’s CAR-T monitoring software, Skribe’s cardiac-function patch, and a Prapela crib mattress that vibrates for infants with single-ventricle heart disease. They get early design and testing feedback plus access to FDA labs. Nine slots total, filled by December 4. Regulatory access as the carrot costs the agency little and arrives years before any payment pathway would.
MedTech Dive
5. 💸 Oura can’t find a price and pulls a $2.2B IPO
Oura postponed its Nasdaq listing on September 29 after marketing 50 million shares at $40–44, about $2.1 billion at a $13.5 billion valuation. CEO Tom Hale said the company has “the luxury of choosing our moment.” Bond and oil volatility took the blame; the book was reportedly five times covered but heavy with insider selling. This was the quarter’s test of whether wearables price as health tech or consumer electronics, and it goes unanswered.
Axios
6. 🇪🇺 Sofinnova raises €82M to build medtechs that don’t exist yet
Sofinnova Partners closed an oversubscribed €82 million MD Start IV to found six to eight device companies across Europe and the US over five years, carrying them from inception through clinical milestones. The prior €63 million fund seeded six companies that raised more than €140 million in follow-on, including LimFlow’s sale to Inari for up to $415 million. Company-creation capital is the thinnest layer of the European device stack, and this is 30% more of it.
Sofinnova Partners
7. 💼 Nyxoah hands its US launch to Teleflex’s former CEO
Liam Kelly, who ran Teleflex from January 2018 until January 2026, took over as Nyxoah’s chief executive on October 1, succeeding Olivier Taelman. Genio, the leadless hypoglossal nerve stimulator for obstructive sleep apnea, has had FDA approval since August 2025 and is early into a US market Inspire built and still owns. Handing an early launch to a large-cap operator says the board thinks the bottleneck is commercial execution, not the implant.
Nyxoah
8. 🧾 Carlsmed’s Medicare codes switch on
Medicare reimbursement for Carlsmed’s aprevo personalized lumbar fusion procedures took effect October 1 under three new MS-DRGs created in the FY2027 inpatient final rule. The company also named Tony Jarc, fifteen years at Intuitive, to a new chief product and AI officer role. A dedicated DRG is what turns a personalized implant from a hospital cost problem into a line item, and that gate, not FDA, is where most AI-shaped hardware stalls.
MassDevice
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.